Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;11(11):630-2.
doi: 10.1038/nrclinonc.2014.174. Epub 2014 Oct 14.

Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment

Steven A Rosenberg  1
Affiliations

Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment

Steven A Rosenberg. Nat Rev Clin Oncol. 2014 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests

The author declares no competing interests.

Figures

Figure 1 |
Figure 1 |
Adoptive cell transfer immunotherapy. Cells are obtained from a resected tumour (autologous TILs) or using peripheral lymphocytes genetically engineered to express antitumour T-cell receptors, expanded in vitro and infused to patients after they have received a preparative lymphodepleting regimen. Abbreviation: TIL, tumour-infiltrating lymphocyte.
See this image and copyright information in PMC

References

    1. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 363, 711–723 (2010). - PMC - PubMed
    1. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 366, 2443–2454 (2012). - PMC - PubMed
    1. Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med 366, 2455–2465 (2012). - PMC - PubMed
    1. Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med 363, 422 (2010). - PubMed
    1. Rosenberg SA et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res 17, 4550–4557 (2011). - PMC - PubMed